A Phase 2a Study to Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Cabozantinib in Patients With Localized Clear Cell Renal Cancer
Latest Information Update: 21 Jul 2023
At a glance
- Drugs Cabozantinib (Primary) ; Dendritic cell vaccines (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 20 Jun 2023 Status changed from not yet recruiting to recruiting.
- 14 Jun 2023 Planned initiation date changed from 31 May 2023 to 15 Jul 2023.
- 20 Mar 2023 Planned initiation date changed from 1 Feb 2023 to 31 May 2023.